Delivery Order SPE2DB22D2206-SPE2DB25FHW37
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,632.32 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, with an ultimate completion date of August 27, 2025. The contract utilizes firm fixed price pricing and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, valued at $12,474.24 under a firm fixed-price contract. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply delivery. This...
- The Defense Logistics Agency awarded a $35.5K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Activase 100 mg vials, with completion scheduled for September 10, 2025. The contract is unclassified as a set-aside and represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $60,767.26 for 100 mg vials of Activase on September 12, 2025, with completion expected by September 15, 2025. This firm fixed-price, non-set-aside contract represents a pediatric delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The order will be fulfilled...
- The Defense Logistics Agency awarded a delivery order valued at $21,231.29 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $30,167.83 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials. The contract employs firm fixed price pricing and carries an ultimate completion date of September 23, 2025. This is a non-set-aside competitive award issued as a child contract, with performance to be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,595.40 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials, with an ultimate completion date of September 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $17,019.04 to AmerisourceBergen Drug Corp for 50 mg vials of Activase, a thrombolytic medication used in acute medical emergencies. This firm fixed price contract, awarded on June 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order carries an ultimate...
- The Defense Logistics Agency awarded a $29,205.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Activase 100 mg vials, with an ultimate completion date of September 26, 2025. This non-set-aside competitive award is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHW37Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,231.46 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's place of performance in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999 indefinite delivery contract with DLA Troop Support Medical (designated SPE2DX) through December 2026, which serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies an extensive range of medications and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The company's federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.2k | 7/14/25 |